公开(公告)号：US20240382612A1

公开(公告)日：2024-11-21

申请号：US18648187

申请日：2024-04-26

Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Inventor： Jiaqiang CAI ,  Shuai SONG ,  Tongtong XUE ,  Liang XIAO ,  Hanwen DENG ,  Qiang TIAN ,  Jing WANG ,  Dengnian LIU ,  Liping LIU ,  Haimin YU ,  Zhouning YANG ,  Xu CAO ,  Guoqing ZHONG ,  Lichun WANG ,  Jingyi WANG

IPC: A61K47/68 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D491/22 ,  C07K5/062 ,  C07K16/30 ,  C07K16/32

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

公开(公告)号：US12134655B2

公开(公告)日：2024-11-05

申请号：US17606246

申请日：2020-04-29

Applicant: Absci Corporation

Inventor： Daniele Biasci ,  Goran Rakocevic ,  Berke Cagkan Toptas ,  Ines De Santiago Domingos De Jesus

IPC: C07K16/00 ,  C07K16/30 ,  C07K16/32

Abstract: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.

公开(公告)号：US20240361328A1

公开(公告)日：2024-10-31

申请号：US18646665

申请日：2024-04-25

Applicant: JUN HUANG

Inventor： JUN HUANG ,  YIFEI HU

IPC: G01N33/58 ,  C07K1/13 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783 ,  G01N33/569

CPC classification number: G01N33/58 ,  C07K1/13 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0636 ,  G01N33/56972 ,  G01N33/582 ,  C07K2317/92 ,  C07K2319/22 ,  C07K2319/33 ,  C07K2319/60

Abstract: The present invention discloses a versatile application of a multimer technology for detecting, manufacturing, and profiling chimeric antigen receptor (CAR)-expressing cells. These antigen-multimers exhibit remarkable specificity, sensitivity, and precision in identifying CAR cells. Moreover, they facilitate over 100-fold magnetic enrichment of rare CAR-T cells, enhancing their detectability. Beyond CAR detection, the multimer technology selectively stimulates CAR-expressing cells, both in soluble and surface-bound formats, during CAR-T cell manufacturing. Unlike existing technologies (such as anti-CD28/CD3 magnetic beads) that non-specifically stimulate and expand all T cells, the multimer approach ensures that only CAR-expressing cells are targeted. Consequently, this yields a CAR-T cell product with significantly higher purity, enhancing treatment efficacy. Furthermore, the multimer technology offers flexibility in CAR detection through nucleotide labeling. This enables high-dimensional CAR-T cell profiling via single-cell multi-omics analyses. Antigen multimers can be seamlessly adapted to other CAR systems by switching the antigen ligand.

公开(公告)号：US20240360243A1

公开(公告)日：2024-10-31

申请号：US18630602

申请日：2024-04-09

Applicant: Elevation Oncology, Inc.

Inventor： Birgit M. SCHOEBERL ,  Ulrik B. NIELSEN ,  Michael J. FELDHAUS ,  Arumugam MURUGANANDAM ,  David BUCKLER

IPC: C07K16/32 ,  A61K9/00 ,  A61K31/337 ,  A61K31/517 ,  A61K33/243 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

CPC classification number: C07K16/32 ,  A61K9/0019 ,  A61K31/337 ,  A61K31/517 ,  A61K39/3955 ,  A61K39/39558 ,  C07K16/2863 ,  A61K33/243 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.

公开(公告)号：US12128110B2

公开(公告)日：2024-10-29

申请号：US16648636

申请日：2018-09-19

Applicant: Paul Scherrer Institut

Inventor： Philipp Spycher ,  Roger Schibli ,  Martin Behe ,  Jori Wehrmuller

IPC: C07K16/32 ,  A61K47/68 ,  C07K16/28 ,  C12P21/00

CPC classification number: A61K47/6855 ,  A61K47/6803 ,  A61K47/6889 ,  C07K16/2878 ,  C07K16/32 ,  C12P21/00 ,  C07K2317/24 ,  C07K2317/41

Abstract: The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker having a primary amine residue, said linker having the peptide structure (shown in N->C direction) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, or (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, to a Gln residue comprised in the heavy or light chain of an antibody. Aax(NH2) is an amino acid, amino acid derivative or amino acid mimetic comprising a side chain having a primary amine group.

公开(公告)号：US20240342213A1

公开(公告)日：2024-10-17

申请号：US18416459

申请日：2024-01-18

Applicant: The Trustees of the University of Pennsylvania ,  Wayne State University

Inventor： Carl H. June ,  Michael Milone ,  Yangbing Zhao ,  Lawrence G. Lum ,  Archana Thakur

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783 ,  A61K35/00 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C12N5/0636 ,  A61K35/00 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/43 ,  C07K2319/50

Abstract: The present invention relates to compositions and methods for enhancing T cell metabolism and activity for more effective adoptive T cell therapy. By expressing an chimeric antigen receptor and bispecific antibodies in T cells, the T cells are metabolically enhanced with improved cytotoxicity and resistance to immunosuppression imposed by tumor microenvironments. Certain aspects include modified T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity.

公开(公告)号：US12109238B2

公开(公告)日：2024-10-08

申请号：US17812264

申请日：2022-07-13

Applicant: ImmunityBio, Inc.

Inventor： Laurent H. Boissel ,  Hans G. Klingemann

IPC: A61K35/17 ,  A61K35/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K35/28 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K16/10 ,  C07K16/1018 ,  C07K16/1027 ,  C07K16/1063 ,  C07K16/109 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.

公开(公告)号：US20240327527A1

公开(公告)日：2024-10-03

申请号：US18436554

申请日：2024-02-08

Applicant: ALX Oncology Inc.

Inventor： Marija VRLJIC ,  Jaume PONS

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/54 ,  C07K16/32

CPC classification number: C07K16/2863 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/5428 ,  C07K14/5434 ,  C07K16/2818 ,  C07K16/32 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/62 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C07K2319/50

Abstract: The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N-terminus of the VH is fused to a first polypeptide shield moiety (S1), and the N-terminus of the VL is fused to a second polypeptide shield moiety (S2), wherein S1 comprises a first disease-sensing releasable moiety (DS1) and/or S2 comprises a second disease-sensing releasable moiety (DS2), wherein association of S1 with S2 blocks binding of the ABD to its target, and wherein the ABD does not specifically bind to S1, S2, or association thereof. Composition, methods of treatment using the activatable antibodies, and methods of preparation thereof are further provided.

公开(公告)号：US20240327476A1

公开(公告)日：2024-10-03

申请号：US18634220

申请日：2024-04-12

Applicant: ModernaTx, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: C07K14/47 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/50 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K38/45 ,  A61K38/48 ,  A61K39/395 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K48/00 ,  C07K14/005 ,  C07K14/435 ,  C07K14/475 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C07K19/00 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00

CPC classification number: C07K14/47 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/14 ,  A61K9/145 ,  A61K9/5031 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/1767 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/215 ,  A61K38/36 ,  A61K38/363 ,  A61K38/44 ,  A61K38/45 ,  A61K38/4833 ,  A61K38/4846 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0066 ,  A61K48/0075 ,  C07K14/005 ,  C07K14/435 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C12N9/0069 ,  C12N9/1051 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/644 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y304/21005 ,  C12Y603/02019 ,  A61K9/0019 ,  A61K38/00 ,  A61K48/00 ,  C07K14/475 ,  C12N2840/00 ,  C12N2840/85 ,  C12Y304/21022

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US12098203B2

公开(公告)日：2024-09-24

申请号：US16608555

申请日：2018-06-04

Applicant: Numab Therapeutics AG

Inventor： David Urech ,  Tea Gunde ,  Sebastian Meyer ,  Christian Hess ,  Alexandre Simonin

IPC: C07K16/44 ,  C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2809 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

Abstract: This invention relates to a hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively, and wherein one of said variable domain pairs is specific for human serum albumin and the other said variable domain pair is specific for human CD3.